Adaptimmune Therapeutics (ADAP)

• Market cap: $14.8M
• 1 day: 10.89%
• 5 days: 38.96%
• 1 month: -27.08%
• 3 months: -77.23%
• 6 months: -87.87%
• Year to date: -91.02%
• 1 year: -94.91%
• 5 years: -99.41%
• 10 years: -99.52%
• Sector: Healthcare
• Industry: Biotechnology

About: Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.

Employees: 506

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

36.07% more ownership

Funds ownership: 7.52% [Q1] → 43.59% (+36.07%) [Q2]

21% more capital invested

Capital invested by funds: $22.9M [Q1] → $27.7M (+$4.83M) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 11

3% less funds holding

Funds holding: 66 [Q1] → 64 (-2) [Q2]

53% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 19

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $0.5
• Avg. target: $0.5
• High target: $0.5

1 analyst rating

• positive: 0 0%
• neutral: 1 100%
• negative: 0 0%

Mizuho Graig Suvannavejh

$0.5

Neutral Downgraded

26 Jun 2025